The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2015 Treatment Recommendation Updates for Psoriatic Arthritis Address Comorbidities, New Medications

2015 Treatment Recommendation Updates for Psoriatic Arthritis Address Comorbidities, New Medications

November 16, 2016 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF
This illustrates a patient with psoriasis accompanied by arthritis and other joint problems. Aside from the appearance of red skin lesions and joint inflammation, changes in fingernails and dactylitis (swelling of fingers that create a sausage-like appearance) are characteristic of psoriatic arthritis.

This illustrates a patient with psoriasis accompanied by arthritis and other joint problems. Aside from the appearance of red skin lesions and joint inflammation, changes in fingernails and dactylitis (swelling of fingers that create a sausage-like appearance) are characteristic of psoriatic arthritis.
Evan Oto/Science Source

In May, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published its recommendations for the treatment of psoriatic arthritis (PsA).1 The updated recommendations represent advances in drug development and availability since previous recommendations published in 2009, as well changes in treatment paradigms and the importance of associated aspects of the disease.2

You Might Also Like
  • 2015 Treatment Recommendations for Psoriatic Arthritis
  • New Guideline for the Treatment of Psoriatic Arthritis
  • Psoriatic Arthritis: Recognize, Manage Comorbidities
Explore This Issue
November 2016
Also By This Author
  • 2015 ACR/ARHP Annual Meeting: RA Pathogenesis and Prevention

“The new list of treatment recommendations provides a way for clinicians to keep up with the literature in a field that rapidly evolves,” says Arthur Kavanaugh, MD, a coauthor of the recommendations, and professor of medicine in the Division of Rheumatology, Allergy and Immunology at the University of California–San Diego, La Jolla, Calif. “The recommendations also reflect a growing appreciation of other aspects of the disease, such as the importance of comorbidities, which previous recommendations did not address,” he adds.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Along with including the importance and treatment of comorbidities associated with PsA, the new recommendations include three new classes of drugs that have come to the market since the 2009 recommendations. These include inter­leukin 12- and 23-blocking drugs, an interleukin 17-blocking drug and a small-molecule drug that inhibits phos­­pho­diesterase 4.

“The old recommendations had the tumor necrosis factor inhibitors as the only biologics,” says Atul Deodhar, MD, professor of medicine, and medical director of the Rheumatology Clinic, as well as Immunotherapy Infusion Center, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Ore. “Rheumatologists may not be aware of the appropriate place in the treatment plan for these new class of drugs, so these recommendations are needed to help guide them on how they can be used and when they can be used.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Updated Recommendations

The 2015 updated recommendations were developed by a panel of GRAPPA rheumatologists, dermatologists and patients with PsA, which reviewed the current literature on treatment of key domains of PsA, including arthritis, spondylitis, enthesitis, dactylitis, skin disease and nail disease. New to this update was the inclusion of a review to identify pertinent comorbidities associated with PsA and their effect on treatment.

(click for larger image)TABLE 1: Overarching Principles for PsA ManagementSource: Adapted from Table 1, References 1 and 3.

(click for larger image)
TABLE 1: Overarching Principles for PsA Management
Source: Adapted from Table 1, References 1 and 3.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: 2015, Clinical, comorbidity, drug, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, guideline, Management, Medication, Psoriasis, Psoriatic Arthritis, recommendation, therapyIssue: November 2016

You Might Also Like:
  • 2015 Treatment Recommendations for Psoriatic Arthritis
  • New Guideline for the Treatment of Psoriatic Arthritis
  • Psoriatic Arthritis: Recognize, Manage Comorbidities
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)